%0 Journal Article %1 Setiawan:2015:erv %A Setiawan, D %A Luttjeboer, J %A Westra, T A %A Wilschut, J C %A Suwantika, A A %A Daemen, T %A Atthobari, J %A Wilffert, B %A Postma, M J %D 2015 %J Expert Review Vaccines %K epidemes %N 4 %P 589-604 %R 10.1586/14760584.2014.990386 %T The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective %V 14 %X Addition of the HPV vaccine to available cytological screening has been proposed to increase HPV-related cancer prevention. A comprehensive review on this combined strategy implemented in the Netherlands is lacking. For this review, we therefore analyzed all relevant studies on cost-effectiveness of HPV vaccines in combination with cervical screening in the Netherlands. Most of the studies agree that vaccination in pre-sexual-activity periods of life is cost-effective. Based on published sensitivity analyses, the incremental cost-effectiveness ratio was found to be mainly driven by vaccine cost and discount rates. Fewer vaccine doses, inclusion of additional benefits of these vaccines to prevent HPV-related non-cervical cancers and vaccination of males to further reduce the burden of HPV-induced cancers are three relevant options suggested to be investigated in upcoming economic evaluations.

@article{Setiawan:2015:erv, abstract = {Addition of the HPV vaccine to available cytological screening has been proposed to increase HPV-related cancer prevention. A comprehensive review on this combined strategy implemented in the Netherlands is lacking. For this review, we therefore analyzed all relevant studies on cost-effectiveness of HPV vaccines in combination with cervical screening in the Netherlands. Most of the studies agree that vaccination in pre-sexual-activity periods of life is cost-effective. Based on published sensitivity analyses, the incremental cost-effectiveness ratio was found to be mainly driven by vaccine cost and discount rates. Fewer vaccine doses, inclusion of additional benefits of these vaccines to prevent HPV-related non-cervical cancers and vaccination of males to further reduce the burden of HPV-induced cancers are three relevant options suggested to be investigated in upcoming economic evaluations.}, added-at = {2017-03-16T16:17:28.000+0100}, author = {Setiawan, D and Luttjeboer, J and Westra, T A and Wilschut, J C and Suwantika, A A and Daemen, T and Atthobari, J and Wilffert, B and Postma, M J}, biburl = {https://www.bibsonomy.org/bibtex/24aaeaccbf31144a8588e5df8462d18e6/krevelen}, description = {The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective. - PubMed - NCBI}, doi = {10.1586/14760584.2014.990386}, interhash = {5d6b97eb05f6ccbc84919c4fb0f63467}, intrahash = {4aaeaccbf31144a8588e5df8462d18e6}, journal = {Expert Review Vaccines}, keywords = {epidemes}, month = apr, number = 4, pages = {589-604}, pmid = {25482311}, timestamp = {2017-03-16T16:28:41.000+0100}, title = {The cost-effectiveness of {HPV} vaccination in addition to screening: a {D}utch perspective}, volume = 14, year = 2015 }